⚡️ INSIGHT: While many platforms rely on automated bots, this one gives clients direct access to a real human support team.https://t.co/6E7P6KTwwB[Brought to you by @iTrustCapital] ...

Summary of CareDx Conference Call Company Overview - **Company**: CareDx, a leader in transplant rejection diagnostics, founded in 1998 and went public in 2014 under the ticker CDNA [6][8] - **Employees**: Over 750, including 100 scientists and researchers, 200 commercial team members, and 80 software engineers [6] - **Market Position**: CareDx is the market leader in solid organ transplantation, supporting over 200 transplant centers in the U.S., which is approximately 80% of all transplant centers [9] Industry Context - **Transplant Waiting List**: Approximately 100,000 patients are on the transplant waiting list, with a new patient added every 8-10 minutes [5] - **Growth Market**: Solid organ transplantation is a growth market driven by annual transplant volume, advances in technology, and government incentives [9] Core Products and Innovations - **Testing Services**: CareDx has performed over 1 million tests for transplant patients, with 200,000 tests conducted in 2025 alone [9] - **AlloSure**: A non-invasive blood test to detect organ injury and assess rejection risk, first clinically validated donor-derived cell-free DNA test [12][13] - **Transplant Plus Strategy**: A roadmap to extend beyond solid organ transplant, including advancements in hematologic cancers with the AlloHeme test [10][17] Financial Highlights - **Q4 2025 Results**: Revenue of $108 million, a 25% increase year-over-year; testing volume of 53,000 tests, up 17% [14][21] - **Full Year 2025 Results**: Total revenue of $380 million, up 14% year-over-year; testing service revenue of $275 million, up 10% [23] - **Adjusted EBITDA**: $32 million for the year, a 14% increase [24] - **Cash Position**: Ended 2025 with $201 million in cash and no debt [24] Growth Strategy - **Revenue Guidance for 2026**: Expected revenue of $420 million-$444 million, representing approximately 14% year-over-year growth [25] - **Testing Services Revenue**: Projected to be $306 million-$326 million with a testing volume of 220,000-228,000 tests [25] - **Operational Efficiency**: Focus on reducing operating expenses as a percentage of revenue, aiming for a modest 63% in 2026 [32] Market Dynamics - **Concentration in Market**: CareDx operates in a concentrated transplant market, allowing for deeper relationships with clinicians and increased revenue per account [27][29] - **Solution Selling Model**: Centers using three or more products see twice the testing volume and revenue compared to those using fewer products [14][30] Future Outlook - **Integration with Epic Systems**: Significant focus on Epic integrations to streamline customer experience and support volume growth [16][18] - **Clinical Evidence Strategy**: Advancing translational research and observational studies to reinforce physician adoption and market access [19][20] Key Risks and Considerations - **Regulatory Risks**: Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from projections [4] - **Market Competition**: The need to maintain leadership in precision diagnostics amidst evolving technologies and competitive pressures [15][32] This summary encapsulates the key points discussed during the CareDx conference call, highlighting the company's position, financial performance, growth strategies, and market dynamics.

Spending on artificial intelligence (AI) is not slowing, but remains hot at the start of 2026. Leading cloud providers are planning significant increases to their capital spending budgets in 2026, and the social media giant Meta Platforms is following suit. During its fourth-quarter earnings call, Meta said it will spend up to $135 billion this year to support AI initiatives across its Superintelligence Labs and core business. This spells growing demand for top chip and server suppliers for the company's ...

Summary of Conference Call Company and Industry Overview - **Company**: Moody's Investors Service - **Industry**: Credit Ratings and Financial Analytics Key Points and Arguments Credit Market Conditions - Credit conditions are currently benign with spreads near historically tight levels, hovering around 300 basis points despite recent market volatility [1][2] - The expectation is for spreads to normalize towards 400-500 basis points, potentially requiring a credit recession to trigger this change [1][2] Revenue and Issuance Expectations - Revenue for the first quarter is expected to be on a calendarized basis about 25%, not indicating a growth rate [3] - Anticipated 25% increase in M&A activity, with a portion involving debt, particularly in data centers and power generation [4] - The pro-growth agenda of the current U.S. administration is expected to support issuance [4] Economic Risks - Prolonged geopolitical conflicts could reduce investor confidence, impacting credit spreads [4] - Rising energy prices and inflation may delay expected rate easing, increasing market volatility [5][6] Interest Rates and Financing - Elevated long-term rates may allow for longer-dated paper issuance, particularly in infrastructure and energy sectors [7][8] - Moody's expects around 750-800 new mandates this year, with a focus on the nature of assets needing financing [8] Pricing Power and Competitive Dynamics - Moody's ratings provide a significant pricing advantage, with a 22% savings on coupon rates for rated bonds compared to unrated ones [11][12] - Continuous engagement with clients to maintain pricing power and address any pushback [9] AI and Operational Efficiency - Moody's is leveraging AI to enhance operational efficiencies, processing approximately $6.6 trillion in debt ratings annually [20] - AI tools are expected to streamline data processing and improve credit analysis timelines [21] Market Position in Private Credit - Moody's has seen a 70% year-over-year growth in private credit-related deals, indicating a strong competitive position in both private and public credit markets [31][33] - The complexity and volume of private credit transactions are increasing, driving demand for Moody's services [33] AI Integration and Competitive Moat - Moody's has built a substantial proprietary data set, which is crucial for embedding trusted context in AI analytics [38] - The company is embedding AI into its products, with strategic customers showing significant growth [41][42] Final Remarks - Moody's is positioned as a durable and compounding business with solid market positions in ratings and analytics [43] - The integration of AI into financial decision-making processes enhances Moody's competitive edge [44]

Citi Names New Brazil Chief as Marangon Moves to Global Role https://t.co/2C1LUJx4n4 ...

🚨 🚨 🚨 🚨 🚨 🚨 2,100 #BTC (143,773,056 USD) transferred from unknown wallet to Coinbase Institutionalhttps://t.co/9RGrX4lUeG ...

RT Messari (@MessariCrypto)State of @1inch Q4Key Update: 1inch rebranded and now offers 1inch Business and 1inch Personal. 1inch also introduced Aqua, a capital-efficient, shared liquidity architecture expanding the protocol beyond aggregation.QoQ Metrics 📊• Aggregation Volume ↓ 50.5% → $244.9M daily• Limit Order Volume ↑ 19.9% → $104.4M daily• Fusion Volume ↑ 22.6% → $82.8M daily• Fusion+ Volume ↓ 38.6% → $1.47M median daily• Aggregator Market Share → 25.2% ...

RT John Hyatt (@John__Hyatt)NEW @Forbes: Block was meant to be Jack Dorsey's Twitter do-over.Instead he repeated his same mistakes, losing focus and hiring too quickly.https://t.co/7ilkRpSW7j ...

https://t.co/L4k9n1BcF4 ...

RT Andrew Tate (@Cobratate)Me in Dubai while the bombs fall 🕺🏽 https://t.co/fKYDbMcEaw ...